Arcellx (ACLX) Non-Current Deffered Revenue (2021 - 2025)
Arcellx's (ACLX) quarterly Non-Current Deffered Revenue came in at $53.1 million in Q4 2025, down 30.13% year-on-year from $76.0 million in Q4 2024, and up 1.28% quarter-over-quarter from $52.4 million in Q3 2025.
Arcellx (ACLX) Non-Current Deffered Revenue (2021 - 2025) Analysis & Trends
Arcellx's Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $53.1 million for Q4 2025.
- On a quarterly basis, Non-Current Deffered Revenue fell 30.13% year-over-year to $53.1 million in Q4 2025; TTM through Dec 2025 was $53.1 million, a 30.13% decrease from a year earlier, with the FY2025 full-year figure at $53.1 million, down 30.13% from the prior year.
- Non-Current Deffered Revenue advanced to $53.1 million in Q4 2025 per ACLX's latest filing, from $52.4 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $170.7 million in Q4 2023 and bottomed at $1.9 million in Q4 2021.
- The 4-year median for Non-Current Deffered Revenue is $82.6 million (2024), against an average of $86.6 million.
- Biggest YoY gain for Non-Current Deffered Revenue was 5.96% in 2024; the steepest drop was 55.47% in 2024.
- Year by year, Non-Current Deffered Revenue stood at $1.9 million in 2021, then jumped by 8906.49% to $170.7 million in 2023, then plunged by 55.47% to $76.0 million in 2024, then tumbled by 30.13% to $53.1 million in 2025.
- Per Business Quant, the three latest ACLX Non-Current Deffered Revenue figures stand at $53.1 million (Q4 2025), $52.4 million (Q3 2025), and $59.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 53.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.10 Mn |
| Sep 30, 2025 | 52.43 Mn |
| Jun 30, 2025 | 59.92 Mn |
| Mar 31, 2025 | 69.45 Mn |
| Dec 31, 2024 | 76.00 Mn |
| Sep 30, 2024 | 82.61 Mn |
| Jun 30, 2024 | 96.08 Mn |
| Mar 31, 2024 | 112.07 Mn |
| Dec 31, 2023 | 170.67 Mn |
| Sep 30, 2023 | 121.09 Mn |
| Jun 30, 2023 | 124.27 Mn |
| Mar 31, 2023 | 105.76 Mn |
| Dec 31, 2021 | 1.90 Mn |